Literature DB >> 1974914

Expression of human adenosine deaminase in mice transplanted with hemopoietic stem cells infected with amphotropic retroviruses.

V W van Beusechem1, A Kukler, M P Einerhand, T A Bakx, A J van der Eb, D W van Bekkum, D Valerio.   

Abstract

Amphotropic recombinant retroviruses were generated carrying sequences encoding human adenosine deaminase (ADA). Transcription of the human ADA gene was under control of a hybrid long terminal repeat in which the enhancer from the Moloney murine leukemia virus was replaced by an enhancer from the F101 host-range mutant of polyoma virus. Hemopoietic stem cells in murine bone marrow were infected with this virus under defined culture conditions. As a result, 59% of day-12 colony forming unit spleen (CFU-S) stem cells became infected without any in vitro selection. Infected CFU-S were shown to express human ADA before transplantation and this expression sustained upon in vivo maturation. Mice transplanted with infected bone marrow exhibited human ADA expression in lymphoid, myeloid, and erythroid cell types. Moreover, human ADA expression persisted in secondary and tertiary transplanted recipients showing that human ADA-expressing cells were derived from pluripotent stem cells. These characteristics of our amphotropic viruses make them promising tools in gene therapy protocols for the treatment of severe combined immunodeficiency caused by ADA deficiency. In this respect it is also relevant that the viral vector that served as backbone for the ADA vector was previously shown to be nonleukemogenic.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974914      PMCID: PMC2188546          DOI: 10.1084/jem.172.3.729

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

2.  Rapid cell culture assay technic for murine leukaemia viruses.

Authors:  R H Bassin; N Tuttle; P J Fischinger
Journal:  Nature       Date:  1971-02-19       Impact factor: 49.962

3.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

4.  Nucleotide sequence of Moloney murine leukaemia virus.

Authors:  T M Shinnick; R A Lerner; J G Sutcliffe
Journal:  Nature       Date:  1981 Oct 15-21       Impact factor: 49.962

Review 5.  Adenosine deaminase deficiency and severe combined immunodeficiency disease.

Authors:  L F Thompson; J E Seegmiller
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1980

6.  Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells.

Authors:  E Linney; B Davis; J Overhauser; E Chao; H Fan
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

7.  Molecular cloning of human adenosine deaminase gene sequences.

Authors:  S H Orkin; P E Daddona; D S Shewach; A F Markham; G A Bruns; S C Goff; W N Kelley
Journal:  J Biol Chem       Date:  1983-11-10       Impact factor: 5.157

8.  Retrovirus-mediated gene transfer into embryonal carcinoma and hemopoietic stem cells: expression from a hybrid long terminal repeat.

Authors:  D Valerio; M P Einerhand; P M Wamsley; T A Bakx; C L Li; I M Verma
Journal:  Gene       Date:  1989-12-14       Impact factor: 3.688

9.  Cloning of cDNA sequences of human adenosine deaminase.

Authors:  D A Wiginton; G S Adrian; R L Friedman; D P Suttle; J J Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

10.  Isolation of murine pluripotent hemopoietic stem cells.

Authors:  J W Visser; J G Bauman; A H Mulder; J F Eliason; A M de Leeuw
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

View more
  8 in total

1.  Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells.

Authors:  V W van Beusechem; A Kukler; P J Heidt; D Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 2.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 3.  Gene therapy of primary immunodeficiencies.

Authors:  F Candotti; R M Blaese
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Production of infectious recombinant Moloney murine leukemia virus particles in BHK cells using Semliki Forest virus-derived RNA expression vectors.

Authors:  K J Li; H Garoff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 5.  From laboratory expertise to clinical practice: multidrug-resistance-based gene therapy becomes available for urologists.

Authors:  G H Mickisch; F H Schroeder
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

6.  Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo.

Authors:  P M Challita; D B Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

7.  Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells.

Authors:  I Rivière; K Brose; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

Review 8.  Gene therapy: here to stay.

Authors:  I D Dubé; D Cournoyer
Journal:  CMAJ       Date:  1995-05-15       Impact factor: 8.262

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.